Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

Clinical trial NCT04663035 · UNKNOWN

Trial details

NCT number: NCT04663035
Sponsor: Ming Zhao
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Hepatocellular Carcinoma

Start date: 2020-12-21
Primary completion: 2023-12-18
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.